DePuy taps Zebra Medical to bring AI vision to its new Velys digital orthopedic surgery platform

doctor looking at x-ray of spine
Zebra Medical Vision will work with DePuy’s Ireland-based subsidiary to co-develop and commercialize programs that create 3D models from cheaper 2D X-ray images. (Getty/cyano66)

As a part of its new digital orthopedic surgery platform, Johnson & Johnson’s DePuy Synthes division will work with Zebra Medical Vision to supplement its artificial intelligence and imaging analytics efforts. 

DePuy’s Velys Digital Surgery platform will focus first on joint reconstruction procedures by incorporating the company’s existing products such as the Kincise automated surgical mallet system and JointPoint navigation and planning software. 

J&J and DePuy plan to add new technologies to the platform over time including sensors, apps, robotics and patient selection tools to address each point along a continuum of orthopedic care from pre-op planning to post-op rehabilitation and monitoring.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Zebra Medical Vision pens AI diagnostic marketplace pact with Nuance

Zebra Medical, a 2016 Fierce 15 winner, will work with DePuy’s Ireland-based subsidiary to co-develop and commercialize programs that create 3D models from cheaper 2D X-ray images, to enable surgical planning without needing an MRI or CT scan.

RELATED: Johnson & Johnson to take over Verb Surgical, its robotics venture with Verily

“We are thrilled to start this collaboration and have the opportunity to impact and improve orthopaedic procedures and outcomes in areas including the knee, hip, shoulder, trauma, and spine care,” said Zebra Medical co-founder and CEO Eyal Gura. 

“We share a common vision surrounding the impact we can have on patients’ lives through the use of AI, and we are happy to initiate such a meaningful strategic partnership, leveraging the tools and knowledge we have built around bone health AI in the last five years,” Gura added.

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The deal will see GSK pay $50 million and commit to $550 million in milestones for TCRs against two solid tumor targets identified by Immatics.